View Post

Managing CIN in Patients With Breast Cancer

In In The News by Barbara Jacoby

Sources: Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center, Rita Nanda, MD, The University of Chicago Medicine, William J. Gradishar, MD, Northwestern University From: onclive.com Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer. Hope S. Rugo, MD, FASCO: …

View Post

Investigators: Same-Day Pegfilgrastim Is Safe and Effective in Patients Receiving CTX for Breast, Lung Cancer

In Clinical Studies News by Barbara Jacoby

By: Tony Hagen From: centerforbiosimilars.com Same-day pegfilgrastim to combat febrile neutropenia in conjunction with myelosuppressive chemotherapy (CTX) is safe, investigators conclude. Same-day vs next-day administration of pegfilgrastim as prophylaxis against febrile neutropenia (FN) in patients undergoing myelosuppressive chemotherapy (CTX) shows promise despite preexisting concerns this may increase the incidence of FN, investigators reported in studies of patients with lung and …

View Post

FDA Approval Sought for F-627 for Chemotherapy-Induced Neutropenia in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com A biologics license application has been submitted to the FDA for the approval of F-627 as a treatment option for patients with breast cancer who have chemotherapy-induced neutropenia. A biologics license application has been submitted to the FDA for the approval of F-627 (Ryzneuta; formerly efbemalenograstim alpha) as a treatment option for patients with breast …

View Post

Study in JNCCN Identifies Significant Factors for Reducing the Risk of Immunosuppression and Fever in People Being Treated with Chemotherapy

In In The News by Barbara Jacoby

Researchers find the timing and length of use for corticosteroids has a particularly strong impact on the likelihood of severe, life-threatening adverse events for people with cancer New research in the October 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network identifies risk factors for chemotherapy-induced febrile neutropenia (FN) —a dangerously low white blood cell count, which increases the …